Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study

Abstract Background Anti‐angiogenic therapy with bevacizumab (BEV), an anti‐VEGF antibody, plays a critical role in the treatment of ovarian cancer. However, despite an encouraging initial response, most tumors become resistant to BEV over time, and a new strategy that enables sustainable treatment...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Tianyue Zhai, Takashi Mitamura, Lei Wang, Shimpei I. Kubota, Masaaki Murakami, Shinya Tanaka, Hidemichi Watari
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2023-04-01
Σειρά:	Cancer Medicine
Θέματα:	angiogenesis antiangiogenic drug bevacizumab CCR2 inhibitor preclinical drug evaluation
Διαθέσιμο Online:	https://doi.org/10.1002/cam4.5674
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!